课题基金 / 基金详情

BIOTINYLATED ERYTHROCYTES IN PATIENTS WITH SICKLE CELL DISEASE

BIOTINYLATED ERYTHROCYTES IN PATIENTS WITH SICKLE CELL DISEASE
镰状细胞病患者的生物素化红细胞
批准号:
6282870
负责人:
ROBERT S FRANCO
金额:
$2.34万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

ROBERT S FRANCO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SIckle RBC are subject to a number of important cellular changes and selection pressures. In this study, we validated a biotin RBC label by comparison to the standard 51CR label, and used it to study changes that occur in sickle cells as they age. Sickle RBC had a much shorter lifespan than did normal RBC, but the two labels gave equivalent results for both cell types. A variable number of sickle, but not normal, RBC disappeared the circulation during the first few hours after reinfusion. The number of biotinylated sickle reticulocytes was decreased by fifty percent after 24 hours and 75% after 48 hours, with a gradual decrease in the amount of reticulum per cell. The labeled sickle cells exhibited major density increases during the first four to six days after reinfusion, with smaller changes thereafter. A small population of very light, labeled sickle RBC was essentially constant in number after the first few days. HbF content was determined in isolated biotinylated sickle RBC after reinfusion, allowing an estimate of lifespan for F cells and non-F cells. The lifespan of sickle B-RBC lacking HbF was estimated to be about two weeks, whereas F cells survived six to eight weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BIOTINYLATED ERYTHROCYTES IN PATIENTS WITH SICKLE CELL DISEASE
Biotinylated Erythrocytes in Patients with Sickle Cell Disease
EFFECT OF THERAPY ON SICKLE CELL HYDRATION AND SURVIVAL
EFFECT OF THERAPY ON SICKLE CELL HYDRATION AND SURVIVAL
海外基金